PHARMA MAR, S.A. 14/09/2021 08:28 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Australia Register number: 11654